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Treatment of ankylosing spondylitis and extra-articular
manifestations in everyday rheumatology practice
Dirk Elewaut1 and Marco Matucci-Cerinic2
The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily
affecting the SI joints. In addition to inflammatory back pain, AS patients are also more likely to experience extra-articular manifestations
belonging to the SpA concept which can affect the eyes, the gastrointestinal tract and the skin and other related inflammatory conditions. This
review focuses on current progress in treatment options in SpA with special emphasis on extra-articular features. TNF inhibition has
demonstrated effectiveness in the treatment of AS symptoms and all currently available anti-TNF agents appear to have similar efficacy.
However, the efficacy of anti-TNF agents varies in the treatment of extra-articular manifestations and comorbidities. Analyses of trials of anti-
TNF agents in patients with AS have revealed significant reductions in the incidence of flares of uveitis and IBD with infliximab and
adalimumab (uveitis only) treatment but not with etanercept. All three anti-TNF agents (infliximab, adalimumab, etanercept) have demon-
strated efficacy in psoriasis (not associated with AS). When evaluating as to which agent to use in the treatment of AS, an important
consideration is the overall well-being of the patient. This should include any additional inflammatory burden that manifests in other parts
of the body, which may currently be subclinical. Based on current evidence, among TNF inhibitors, the monoclonal antibodies (infliximab and
adalimumab) are more appropriate than etanercept if extra-articular manifestations or comorbid conditions are present or suspected. To date,
infliximab appears to be the best studied agent with a wide spectrum of proven efficacy.
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Introduction
SpAs [1] are overlapping, chronic, inflammatory rheumatic dis-
eases that primarily include AS, ReA, arthritis with associated
IBD and PsA [2]. SpAs are the most common rheumatic diseases,
affecting 0.5–1.9% of the population [3–6]. Evidence supports a
role of HLA-B27 allele as genetically linking to the pathophysiol-
ogy of AS and other SpAs [2]. The main links between these
diseases include association with HLA-B27, similar patterns of
peripheral joint involvement with asymmetrical arthritis and
the possible occurrence of sacroiliitis, spondylitis, enthesitis and
uveitis. The leading clinical symptoms for all SpA subsets
are inflammatory back pain and/or asymmetrical arthritis
predominantly of the lower limbs [1].
AS, the most common and severe subtype of the SpAs is
a chronic inflammatory disease primarily affecting the SI joints
[1, 7] with an estimated prevalence of 0.2 and 1.2% [3, 5, 6, 8].
Typically manifesting in the third decade of life [2, 9, 10], AS is
2.5-times more common in men than women [11].
It is now clear that inflammation in AS is strongly dependent
upon TNF-. Dense mononuclear infiltrates containing T cells
and macrophages, secreting TNF, have been observed in joints
of AS patients [12–14]. Additionally, trials of TNF- inhibitors
in AS have yielded impressive results [15–18], supporting the
pathogenic role of TNF- in AS.
Inflammatory back pain is the key clinical symptom in AS [19].
Additionally, radiographic evidence of sacroiliitis is required for
the diagnosis of AS [20]. In early and acute stages of sacroiliitis,
findings on conventional radiography can be normal, making
diagnosis difficult, although other imaging techniques may
show SI inflammation [21]. However, in more advanced disease,
sclerosis and erosions are evident in radiographic images of
the SI joint; as disease progresses, ankylosis, the most character-
istic feature of AS, can cause these entities to vanish from the
radiograph [21].
Although AS is primarily a disease of the axial skeleton,
peripheral joint involvement occurs in up to 70% of the patients
[22]. Involvement of the axial joints, including shoulders and hips,
is more common in AS than the involvement of more distal joints
[23]. Unfortunately, axial disease has proven very difficult to
treat and the conventional DMARDs used to treat RA have
proven ineffective [24–26].
In addition to AS, HLA-B27 is strongly associated with ReA,
PsA, acute anterior uveitis, IBD and aortic incompetence with
heart block [2]. Other parts of the body besides the joints that
are affected by SpAs are known as extra-articular manifestations,
which can affect the eye, urogenital tract, gastrointestinal (GI)
tract and skin. An epidemiological study of 847 patients in
Belgium who fulfilled the modified New York criteria for AS
found that 42% had one or more extra-articular manifestations,
including acute anterior uveitis (27%), IBD (10%) and psoriasis
(11%) [7]. This illustrates the relatively high frequency of extra-
articular manifestations in AS patients. Additionally, 83% of this
population was found to carry the HLA-B27 allele [7]. Other
epidemiological studies have found even higher incidences of
extra-articular manifestations [27, 28], thought to be a
consequence of uncontrolled systemic inflammation (Table 1).
Extra-articular manifestations can also affect the kidneys, lungs,
heart and bones.
Most clinicians understand that the presence of comorbid
conditions reduces the quality of life (QoL) of patients. Two
patients with the same degree of back pain and radiographic
findings will not share the same QoL if one of them also has
psoriasis, for example. The presence of comorbidities is a signifi-
cant determinant of the mental health-related impact of AS on
QoL [42]; therefore, it is important to screen for extra-articular
manifestations and comorbid conditions in patients diagnosed
with AS to ensure appropriate management. Clinical signs such
as diarrhoea, skin/nail problems, eye discomfort, redness or pain
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and unexplained weight loss or fever should be considered
‘red flags’ for further investigation. The presence of extra-articular
manifestations or comorbid conditions can guide treatment
decisions and address the underlying cause of inflammation.
Extra-articular manifestations related to the SpA concept
Eye. Acute anterior uveitis (iritis) is a common extra-articular
manifestation in AS patients [28]. Uveitis is usually monolateral
and characterized by painful red eye with photophobia, increased
tear production and blurred vision [43]. Inflammation occurs
within the anterior chamber and may involve the uveal tract
in either the iris or the ciliary body, with spillover of vitreous
inflammatory cells into the space behind the lens. The initial
episode usually has an acute onset—1- to 2-day prodrome of
mild eye discomfort followed by the development of marked red-
ness and pain—and is unilateral [44]. There is a strong tendency
for recurrence, which frequently occurs in the contralateral eye
[44]. Uveitis usually resolves within 2–3 months without residual
visual impairment [45]. If inadequately treated, it can progress
to hypopion, synechia, cataract, glaucoma or vision loss [43].
In PsA and IBD, uveitis may be unilateral or simultaneously
bilateral, insidious in onset, chronic in duration and may involve
the posterior eye [46–48].
Patients with AS have a 20–30% chance of developing uveitis
during the course of their disease [44]. Conversely, patients with
an acute onset anterior uveitis that are HLA-B27 positive are
highly likely to have an associated sacroiliitis and/or peripheral
arthritis [44]. Indeed, incidence rates have been reported of up to
90% of patients with HLA-B27-associated acute anterior uveitis
that have definite or possible AS [44].
Corticosteroids are a mainstay of uveitis treatment. Topically
applied prednisolone acetate is well absorbed across the cornea
and can be effective but is less so for posterior inflammation.
Dilating drops, such as scopolamine, may be used to prevent
posterior synechiae and to relieve pain resulting from ciliary
muscle spasms that control pupil size. Periocular corticosteroid
injections can also be used, as well as brief courses of oral corti-
costeroids, for persistent inflammation despite topical therapy.
NSAIDs and cytotoxic drugs, such as SSZ and MTX, have a
limited role in treatment [44].
High levels of TNF- have been shown in the aqueous humor of
patients with clinical uveitis [49]; therefore, TNF- inhibitor treat-
ment seems to be a logical approach. A small 46-week trial of the
TNF- inhibitor infliximab in patients with intermediate and/or
posterior uveitis, intolerant or unresponsive to standard therapy,
demonstrated effectiveness with significant improvements in visual
acuity [50]. A meta-analysis of studies using the TNF- inhibitors
etanercept and infliximab revealed that both agents significantly
reduced the incidence of uveitis flares compared with placebo
(placebo: 15.6/100 patient-years; infliximab: 3.4/100 patient-
years; etanercept: 7.9/100 patient-years; P¼ 0.01; TNF-
inhibitors vs placebo) in patients with AS. When either agent
was analysed separately, the difference between infliximab and
placebo was highly significant (P¼ 0.005) compared with the
difference between etanercept and placebo (P¼ 0.05). While a
trend towards a greater reduction in uveitis incidence with
infliximab therapy over etanercept was evident, this, however,
did not reach significance (P¼ 0.08) [29].
A retrospective study of patients with SpA further confirms the
efficacy of TNF- inhibitors in reducing acute uveitis flares
(Fig. 1) [51]. Patients receiving TNF- inhibitors were selected
from a hospital database, and those who experienced a uveitis
flare at any time point were identified. Fifty patients with SpA
and uveitis were selected, and 46 received sufficient follow-up
for analysis following initiation of TNF- inhibitor treatment:
33 patients received anti-TNF antibodies [infliximab (n¼ 25) or
adalimumab (n¼ 8)] and 13 patients received the soluble TNF
receptor (etanercept). TNF- inhibitors reduced the incidence
of uveitis flares from 51.8/100 patient-years prior to anti-TNF
TABLE 1. Extra-articular manifestations related to the SpA concept and their
prevalence in AS
Extra-articular manifestation Prevalence in patients with AS, %
Anterior uveitis 30–50 [28, 29]
IBD 5–10 [28, 30]
Subclinical inflammation of the gut 25–49 [31–33]
Cardiac abnormalities
Conduction disturbances 1–33 [34]
Aortic insufficiency 1–10 [34]
Psoriasis 10–20 [21, 28]
Renal abnormalities 10–35 [35, 36]
Lung abnormalities 40–88 [37–39]
Airway disease 82 [39]
Interstitial abnormalities 47–65 [38, 39]
Emphysema 9–35 [37, 39]
Bone abnormalities [40, 41]
Osteoporosis 11–18 [41]
Osteopenia 39–59 [41]
Mean number of uveitis flares per 100 patient-years
16.8 year
1.4 year
16.2 year
0.6 year
11.5 year
1.2 year
Mean treatment period
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FIG. 1. Incidence of uveitis flares prior to and during treatment with TNF- inhibitors [51].
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treatment to 21.4/100 patient-years while receiving anti-TNF
treatment (P¼ 0.03). However, this analysis demonstrated
a clear difference between etanercept and the anti-TNF antibodies
(infliximab and adalimumab); the incidence of uveitis remained
unchanged with etanercept treatment (54.6 vs 58.5/100 patient-
years; P¼ 0.92), whereas it was dramatically reduced following
anti-TNF antibody treatment (infliximab: 47.4 vs 9.0/100
patient-years; P¼ 0.008, adalimumab: 60.5 vs 0/100 patient-
years; P¼ 0.04). Two patients who never had uveitis before
anti-TNF treatment developed uveitis while taking etanercept.
However, patients receiving etanercept were less likely to be
receiving additional DMARDs, which may have influenced
the incidence of flares, although this was not statistically signi-
ficant [51]. An open-label study with adalimumab demonstrated
reduced rates of uveitis flares in patients with AS (n¼ 1250).
Patients received adalimumab 40mg every other week for
12 weeks. There was a significant reduction in uveitis flare rates
per 100 patient-years when comparing the flare rates before
adalimumab therapy to flare rate during adalimumab therapy
(15 vs 7.4/100 patient-years; P< 0.001) Overall, adalimumab
reduced the flare rates by 50% [52].
GI tract. A strong relationship exists between gut and
joint inflammation in SpA [53]. Ileocolonoscopic evidence of
microscopical signs of gut inflammation is present in up to 60%
of the AS patients, unrelated to GI complaints [53]. Over time,
a fraction of these patients evolved into full-blown IBD [54].
Furthermore, when investigated, remission of joint inflammation
was always connected with a disappearance of gut inflammation
[53]. Evidence for TNF involvement in the pathogenesis of IBD
associated with AS has been provided by studies in mice [55].
Deletion of TNF sequence elements rich in A and U nucleotides
[AU-rich elements (AREs)] from the mouse genome resulted in the
development of chronic inflammatory arthritis and Crohn’s-like
disease in mutant mice, and features of SpA [56]. The absence of
AREs affects the mechanisms for TNF mRNA destabilization
and translational repression, resulting in overexpression of
TNF [55]. The origin of the so-called gut–joint axis is not formally
known yet but several hypotheses exist including a role for
stromal cells [56, 57].
IBD has been identified in up to 10% of the patients with AS
[28]. Conversely, AS is diagnosed in 3–10% of the patients with
IBD, although radiological evidence of sacroiliitis is reported to be
present in 14–46% [58]. Indeed, SpA-related musculoskeletal
symptoms are the most common extra-intestinal manifestations
of IBD [59].
Treatment of IBD has traditionally relied on corticosteroids to
reduce flares and immune modulators, such as 5-aminosalicylic
acid, AZA, mercaptopurine and MTX, to maintain remission
[60]. However, surgical treatment would often be warranted.
The advent of biologic treatments has provided an alternative
option to surgery in patients who are refractory or intolerant of
other medical treatment [60].
Infliximab and adalimumab are licensed for the treatment of
Crohn’s disease (CD) in Europe and the USA [61–64], whereas
infliximab is additionally licensed for the treatment of ulcerative
colitis (UC) and paediatric CD in Europe and the USA [61].
However, etanercept has not proven effective in IBD [65].
Whereas etanercept is efficacious in treating the spinal pathology
and arthritis associated with AS, case reports reveal that asso-
ciated CD remains persistent or flares during etanercept therapy
[66]. Certolizumab pegol is another licensed treatment option
for patients with CD in the USA [67].
A meta-analysis of trials of TNF- inhibitors in AS patients
investigated the incidence of flares or new onset of IBD (Fig. 2)
[59]. Nine trials were evaluated: seven placebo-controlled and two
open labels, with a total of 1130 patients included. The incidence
rates for flares or new onset of IBD were 0.2, 2.2, 2.3 and 1.3 per
100 patient-years during treatment with infliximab, etanercept,
adalimumab and placebo, respectively. While there was no signi-
ficant difference in the incidence rates between placebo and the
TNF- inhibitors, there was a significant difference in favour
of infliximab over etanercept (P¼ 0.001) and adalimumab
(P¼ 0.02). Furthermore, in patients with a history of IBD
flares, flares were 18 times more likely to occur in etanercept-
treated AS patients and 4.2 times more likely in adalimumab-
treated AS patients than in infliximab-treated AS patients. Data
with adalimumab were quite limited due to the total period of
exposure of 132.3 patient-years compared with 618 patient-years
for infliximab and 625.4 patient-years for etanercept [59]. An
open-label study with adalimumab (n¼ 1250) demonstrated
some improvement in IBD in patients with AS. Symptomatic
IBD was reported in 4.7% of the patients at baseline. Of those
patients, 20% at baseline reported no IBD interference in the
past 7 days, and at 12 weeks 48% of the patients reported this
response [68].
Additionally, it is recommended that adalimumab be adminis-
tered in much higher initial ‘induction’ doses when given for the
treatment of CD (80mg) than would be used in the treatment
of AS (40mg) [63]. The efficacy of adalimumab in UC is also
currently unclear. These factors may help explain the difference
in flare incidence between adalimumab and infliximab.
Skin. Cutaneous manifestations can be associated with SpAs.
Psoriatic skin lesions manifest before arthritis symptoms in
three-quarters of patients with PsA [69]. Psoriasis has been
observed in up to 20% of the patients as a secondary disorder
in AS, regardless of age of onset [28]. Patients with concomitant
psoriasis tend to exhibit more peripheral joint involvement [70].
Involvement of the SI joint and the spine occur in 5% of the
patients with psoriasis [21]. Furthermore, the presence of extra-
articular manifestations can have implications on the degree of
disease involvement and progression. In a large AS patient
sample, association with psoriasis was found to produce a
worse disease course than either primary AS or AS associated
with IBD [71].
Bone. Although osteoporosis and osteopenia are well-established
complications of AS, the exact mechanisms remain unclear [72].
A large proportion of AS patients (63%) are either osteopenic or
osteoporotic [40] affecting up to 59 and 18% of the patients with
AS, respectively [41]. Importantly, a correlation has been shown
between low femoral BMD and risk of vertebral fractures in
AS patients [73]. Grataco´s et al. [74] have shown in a follow-up
of 19 months that active AS patients without bony ankylosis had
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FIG. 2. Incidence of IBD flares or new-onset disease according to TNF- inhibitor
treatment received [59].
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a bone mass reduction superior to inactive AS patients. Bone loss
in active AS patients, in particular at the femoral neck, has
also been confirmed [75].
In AS, preventive treatment for bone loss and vertebral
fracture prevention are rarely used: analgesia with NSAIDs and
regular physiotherapy tend to be the norm [38]. Recent studies,
however, have shown promising results in terms of bone density
improvements using TNF- inhibitors. In a subanalysis of the
24-week ASSERT trial, significant increases in mean spinal
BMD were observed in AS patients treated with infliximab
compared with placebo where BMD remained unchanged (2.5 vs
0.5, P< 0.001) [76]. The impact on vertebral fracture frequency
is still unclear.
Heart. Cardiac abnormalities including conduction disturbances
and aortic insufficiency are not uncommon in patients with AS.
Both cardiac and aortic tissue have shown intimal proliferation of
small arteries and fibrosis, similar to that seen adjacent to affected
joints. [77] Prevalence estimates vary widely from 1 to 33%
for conduction disturbances and from 1 to 10% for aortic insuffi-
ciency [34, 78]. AS is associated with an excess mortality from
cardiovascular disease of around 20–40% [27]. Inflammation
is well known for its role in the initiation and progression of
atherosclerosis, and the chronic inflammation and immune
dysregulation associated with AS is thought to be involved in
accelerated atherosclerosis [79]. A higher prevalence of athero-
sclerosis has been demonstrated in patients with AS compared
with controls, which may help explain the increased cardiovascu-
lar risk in the AS population [80]. Anti-TNF- treatment is
thought to have a favourable effect in reducing cardiovascular
risk in patients with chronic inflammatory disorders. In a study
of 60 patients with RA, AS and PsA (24, 26 and 10 patients,
respectively), infliximab treatment modified the unfavourable
lipid profile in patients, inducing a modest, but sustained increase
in serum high-density lipoprotein cholesterol (HDL-C) levels [81].
Additionally, anti-TNF- treatment with etanercept was shown
to significantly improve microvascular function for both
endothelium-dependent vasodilation (P¼ 0.03) and capillary
recruitment (P¼ 0.006) in patients with AS [82].
Lungs. Pulmonary abnormalities are also documented in patients
with AS [39]. It has been proposed that a potential mechanism
could be a direct result of the same mechanism affecting the
joints [83]. Prevalence estimates vary widely, with pulmonary
abnormalities being reported in 40–88% of the AS patients
using high-resolution CT [37–39]. The abnormalities include
evidence of airway disease (82%) and interstitial abnormalities
(47–65%), and emphysema (9–35%) [37–39], thickening of
the interlobular septa (33%), mild bronchial wall thickening
(29%) and pleural thickening (29%) may be detected [84].
If alveolitis is found, it is mainly characterized by lymphocytosis
at bronchoalveolar lavage [85].
Kidneys. The incidence of renal abnormalities increases in
patients with AS. Likely causes include an increased incidence
of glomerulonephritis, particularly associated with deposition of
immunoglobulin A (IgA)–containing immune complexes, and
renal amyloid deposition (amyloidosis) [35, 36]. Usually amyloi-
dosis is secondary (amyloid A, reactive) and may be characterized
by proteinuria and renal insufficiency and accompanied by malab-
sorption and bleeding. Amyloidosis is more prevalent in aggres-
sive and active AS and in older patients with long-standing
disease. At the moment of abdominal subcutaneous fat aspiration,
most patients (80%) had subclinical amyloid deposits [86, 87].
The incidence of renal abnormalities (including IgA glo-
merulonephritis, microscopic haematuria, microalbuminuria and
decreased renal function and creatinine clearance) has been shown
to range from 10 to 35% in patients with AS [86, 87]. Some
case reports suggest the potential role of TNF- inhibitors in
improving AA amyloidosis. In this report, patients were treated
with etanercept over 1 year [88].
Are there differential effects with anti-TNF therapies?
The use of TNF- inhibitors (infliximab, adalimumab, etanercept)
results in substantial improvements in both signs and symptoms of
AS also contributing to an improved functional status and QoL
[15–18, 89]. The efficacy of TNF- inhibitors in extra-articular
manifestations and comorbid conditions appears to vary from
agent to agent. Etanercept appears to have very little effect on
uveitis and IBD, while the incidence of flares of both conditions
appears to be reduced with infliximab treatment for AS; there are
comparatively relatively little data available for adalimumab at
present [29, 51, 59]. Infliximab has been shown to be very effective
in treating the underlying inflammation present in extra-articular
manifestations [28, 29, 90–93]. Additionally, infliximab has been
proven efficacious in the treatment of psoriasis and in patients
with PsA (both independent of AS).
Modes of action differences of these agents may, at least
in part, explain the differences in their efficacy profiles. Each
molecule of infliximab is believed to bind two TNF- molecules.
Alternatively, three molecules of infliximab are believed to bind to
one TNF- trimer, allowing few or no receptor-binding sites free
on a TNF- molecule (Fig. 3) [94]. Relatively stable complexes
of infliximab have also been shown to form with both soluble and
transmembrane TNF- [94]. Infliximab did not dissociate from
soluble TNF- in radiolabelled TNF--binding assays in the
presence of unlabelled competitor after >3 h of incubation [94].
Additionally, after 2 h of incubation in the presence of excess
unlabelled infliximab, etanercept or soluble TNF, radiolabelled
infliximab did not dissociate from transmembrane TNF. These
results indicated that infliximab/TNF complexes are less
bioactive than soluble TNF dissociated from etanercept [94].
Adalimumab binds both soluble and membrane-bound TNF-
[95] and forms a relatively stable complex. Extensive
FIG. 3. Binding of infliximab and etanercept to cell surface transmembrane TNF. Reproduced with permission from the American Society for Pharmacology and
Experimental Therapeutics [94].
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characterization studies of the TNF--binding characteristics of
adalimumab have not been conducted; therefore, more data are
needed.
Etanercept is a bivalent molecule that binds to the interface of
two TNF subunits in a 1:1 ratio, occupying two of the three
receptor sites on TNF- but leaving the third receptor site open
(Fig. 3) [94, 96]. Etanercept shows little affinity for monomeric
TNF- subunits compared with trimeric TNF- because the
receptor-binding site on the TNF- is in the cleft formed in the
TNF- complex [96].
Etanercept has a high affinity for soluble TNF-; however, the
resultant complex is relatively unstable [96]. Radiolabelled binding
assays found that transmembrane TNF/etanercept complexes
are also relatively unstable. The relative instability of etanercept/
TNF complexes could, in part, explain the observed relative
reduction/absence of efficacy for etanercept in some TNF--
related conditions [94].
These data suggest that of the TNF- inhibitors, the mono-
clonal antibodies (infliximab and adalimumab) may be more
favourable in the treatment of extra-articular manifestations
associated with AS compared with the receptor fusion
protein, etanercept. Although differences among the TNF-
inhibitors have been observed in in vitro or animal models,
head-to-head studies are needed to establish the difference in
efficacy of these agents in treating AS-associated extra-articular
manifestations.
Treatment approach
The evidence that extra-articular manifestations and comorbid
conditions are common and may be serious when associated
with AS suggests that physicians should consider their potential
presence in the patient when selecting a therapy. Emerging knowl-
edge that these manifestations may be consequences of the same
inflammatory pathology should direct the physician to identify a
therapy that will treat the patient as a whole. Achieving suppres-
sion of uncontrolled inflammation throughout all body systems
has the potential to improve patient QoL and outcomes.
Prior to the advent of biologic agents, treatments for AS were
limited to symptomatic relief; no established treatment had been
found to arrest the demineralization of bone or ossification of
ligaments and tendons that are characteristic of advancing
AS [97]. NSAIDs have been the cornerstone of pharmacological
intervention in AS, rapidly reducing inflammatory back pain
[98–104]. However, the use of NSAIDs is often limited by GI
side effects and, after the withdrawal of NSAID treatment,
rebound symptoms of inflammation generally appear within a
few days [105]. A reduction in radiographic progression of AS
with continuous NSAID use, rather than ‘as-required’ use, has
recently been demonstrated in a 2-year randomized controlled
trial [106]. Therefore, NSAIDs should be considered prior to the
initiation of TNF- inhibitors [107].
SSZ, a DMARD used in the treatment of RA, has demon-
strated some efficacy in peripheral arthritis; however, axial
symptoms do not appear to improve [97, 108, 109]. More recently,
TNF- inhibitors have been established as safe and effective for
the treatment of signs and symptoms of active AS [16, 18, 110].
The return of symptoms following cessation of a TNF inhibitor
suggests that TNF inhibitors should be maintained in the long
term to ensure maximum patient benefit [111]. Furthermore,
4-year follow-up data suggest that infliximab may decelerate the
progression of structural changes compared with previously
documented controls. Larger studies are required to confirm
this [112].
Although the goal of treatment is to suppress underlying
inflammation, there is some controversy in the field on the
impact of new bone formation, a hallmark feature in AS. It is
possible that even though there is continued suppression of
inflammation bone formation, ankylosis may occur once the
pathological cascade has been triggered [113]. Data from research
by Lories et al. suggest that BMP signalling plays a key role in the
pathological cascade of bone formation. Controlling inflamma-
tion alone may not be sufficient to inhibit structural progression;
therefore, complementary therapy targeting BMP signalling
may be beneficial [114].
Factors predicting a major clinical response to TNF- inhibitor
therapy in active AS include younger age, shorter disease
duration, better functional status, raised acute-phase reactants,
higher disease activity and widespread inflammation in the spine
as detected by MRI [115, 116]. Regarding the achievement of
a 550% improvement in the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI), there does not appear to be
any patient feature that predicts a response to one TNF- inhibi-
tor over another, and thus there appears to be little to distinguish
TNF- inhibitors in terms of BASDAI response alone [115].
The lack of efficacy of etanercept in CD is widely known and
acknowledged in the international Assessment in Ankylosing
Spondylitis (ASAS) consensus statement for the use of anti-
TNF agents. It is recommended that infliximab is used when
there is underlying CD [107]. This line of thinking can be extra-
polated to consider other extra-articular manifestations and
comorbid conditions, such that the most appropriate treatment
for the entire patient is chosen. Both infliximab and adalimumab
may be suitable options in treating an AS patient with associated
extra-articular manifestations; however, infliximab is the best
studied agent to date.
Conclusions
AS is a disease characterized by sacroiliitis with associated
inflammatory back pain, leading to ankylosis of the spine.
Chronic inflammation associated with AS can also underlie
pathological processes in other parts of the body leading to
extra-articular manifestations and comorbid disease. The extra
burden that additional inflammatory disease manifestations can
place on a patient can result in a reduction in QoL and indicate
worse outcomes. Treating the inflammatory disease process
underlying both the AS and extra-articular symptoms significantly
benefits the patient. While there appears to be no difference in
efficacy for the currently available TNF- inhibitors with regard
to treatment of AS symptoms, there are considerable differences
regarding extra-articular symptoms. Etanercept does not appear
to be effective in reducing the incidence of either IBD or uveitis
flares, while infliximab and adalimumab do appear to have some
effect, although more data are required for adalimumab. All three
agents have demonstrated some level of efficacy in psoriasis
(not associated with AS). There appear to be important pharma-
codynamic and pharmacokinetic differences between the TNF-
inhibitors that may potentially contribute to their efficacy in
different disease states.
Whereas not every patient with AS will exhibit inflammatory
disease also in other organ systems, the incidence of extra-
articular manifestations, including the GI tract, eye, skin, bone,
lung and kidney, is much greater than in the general population
and thus should always be considered. Many patients may have
asymptomatic or low-grade inflammation that has yet to manifest
as full-blown disease, and enquiry about bowel habits, skin
problems, nail changes and ocular problems may help to identify
these patients. Once inflammation is identified in more than one
organ system, it would seem sensible to treat the inflammation
throughout the whole body rather than focusing on one area. If
treatment with a TNF- inhibitor is warranted, the monoclonal
antibodies (adalimumab and infliximab) would appear to be
preferred above etanercept for the management of AS with
current or likely future, extra-articular manifestations and
comorbid conditions. However, currently, infliximab is the best
studied monoclonal antibody with a wide spectrum of proven
efficacy.
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Rheumatology key messages
 Chronic inflammation associated with AS can lead to extra-
articular manifestations.
 Consider the overall patient well-being when selecting treatment in
patients with AS.
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